# A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study

> **NCT05394714** · PHASE1 · RECRUITING · sponsor: **Medigen Biotechnology Corporation** · enrollment: 18 (estimated)

## Conditions studied

- Colon Cancer Stage I

## Interventions

- **BIOLOGICAL:** Magicell-NK contains NK cells suspended in 100 mL normal saline

## Key facts

- **NCT ID:** NCT05394714
- **Lead sponsor:** Medigen Biotechnology Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-10
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2025-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05394714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05394714, "A Phase I, Autologous ex Vivo Expanded and Activated NK Cell, Magicell-NK, Infusion for Colon Cancer Post Resection Study". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05394714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*